PT-141 for Erectile Dysfunction:
What the Research Actually Shows

PT-141 (bremelanotide) is FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women; its use for men with erectile dysfunction is off-label. This distinction matters clinically: the mechanism is real and the human trial data exists, but PT-141 for male ED is prescribed outside the scope of its approved indication, and patients should understand that clearly before starting. This article covers what PT-141 actually is, what the clinical evidence shows, and what kind of patient it's most likely to help.

This post is part of our guide to novel ED therapies beyond PDE5 inhibitors. If you haven't read that overview, it provides useful context for why these alternatives exist and who they serve.

How PT-141 Works: A Central Mechanism

The key difference between PT-141 and drugs like sildenafil (Viagra) or tadalafil (Cialis) is where in the body they act. PDE5 inhibitors work peripherally — they relax the smooth muscle in penile blood vessels, increasing blood flow in response to arousal. If you're not aroused, sildenafil doesn't do much. PT-141 acts centrally, in the brain.

Specifically, PT-141 is a melanocortin receptor agonist. It binds to MC3R and MC4R receptors in the hypothalamus — brain regions involved in regulating sexual desire and arousal. Activation of these receptors appears to increase motivation toward sexual activity and modulate the arousal cascade at its neurological origin. It doesn't dilate blood vessels. It doesn't increase nitric oxide. It works upstream, in the desire and arousal circuitry, before the vascular response even begins.

This is why PT-141 is potentially useful for a specific subset of men with ED — those whose dysfunction involves a psychological, desire-based, or neurological component rather than (or in addition to) a purely vascular one.

Clinical Evidence: What the Research Shows

The most relevant clinical data for men with ED comes from a study by Safarinejad and Hosseini (2008), which evaluated PT-141 in men who had already failed PDE5 inhibitor therapy — so-called PDE5 non-responders. This is a difficult-to-treat population, and the results were meaningful: PT-141 showed approximately a 33.5% response rate versus 8.5% for placebo in PDE5 non-responders. That's a roughly four-fold advantage over placebo in men who had no other options.

It's important to be precise about this number. A 33.5% response rate is not high in absolute terms — two out of three men in this trial didn't respond. But the context matters: this is a population in whom sildenafil has already failed. In that specific group, PT-141 offers a meaningful probability of benefit when no other oral or injectable option has worked.

PT-141 is not expected to outperform sildenafil or tadalafil in men who haven't tried PDE5 inhibitors first. For general male ED without prior PDE5 failure, PDE5 inhibitors remain more effective. PT-141 fills a specific niche: the man who has tried the first-line options and failed, or whose ED has a prominent non-vascular component.

Who Is PT-141 Best For?

At Revive, we prescribe PT-141 for men who fit one or more of these profiles:

• PDE5 non-responders: Men who have tried sildenafil and/or tadalafil at adequate doses and have not achieved satisfactory erections.
• Psychological or desire-component ED: Men whose ED appears to have a significant psychological, anxiety-related, or low-desire component — not purely vascular.
• Low libido alongside ED: Men experiencing reduced sexual desire concurrently with ED, where the central mechanism of PT-141 may address both dimensions.
• Post-PDE5 augmentation: In some cases, PT-141 and a PDE5 inhibitor may be used together when neither alone provides sufficient response — this is an area of clinical judgment.

PT-141 is generally not the first drug we reach for in men with uncomplicated vascular ED who haven't tried PDE5 inhibitors. In that scenario, a PDE5 inhibitor prescribed to your local pharmacy — often insurance-covered — is the appropriate starting point. For more on the full landscape of ED options, see our ED & PE Medication Guide.

How PT-141 Is Administered

PT-141 is administered via subcutaneous injection — a small needle inserted under the skin of the abdomen or thigh, similar to how insulin is injected. The injection is taken approximately 45 minutes before anticipated sexual activity.

For men who are unfamiliar with self-injection, this can feel like a significant barrier — but in practice, after the first demonstrated technique, most patients find it straightforward. At Revive, we walk through injection technique at the prescribing appointment so you leave confident in the process. The needle gauge used for subcutaneous injection is small and the injection is largely painless.

PT-141 for male use is available only as a compounded medication in the US — it is not commercially manufactured in an FDA-approved form for this indication. It is typically compounded at a concentration of 1–2 mg per dose, with dosing individualized by your provider based on response and tolerance.

Side Effects

PT-141 has a distinct side effect profile compared to PDE5 inhibitors, primarily because it acts centrally rather than on blood vessels. The most commonly reported side effects include:

• Nausea (most common, reported in approximately 40% of users) — typically mild to moderate, transient, and often manageable by starting at a lower dose. Taking the injection after a light meal can reduce nausea.
• Flushing — warmth or redness, particularly in the face and neck, occurring in a subset of users.
• Transient blood pressure changes — PT-141 can cause transient increases or decreases in blood pressure, which is generally mild but warrants awareness in men with cardiovascular conditions.
• Injection site reactions — mild redness, swelling, or bruising at the injection site, as with any subcutaneous injection.
• Hyperpigmentation — due to its melanocortin activity, PT-141 may cause darkening of skin or new moles with long-term or high-dose use. This is a known class effect of melanocortin agonists.

PT-141 does not cause the visual side effects or severe headaches sometimes associated with PDE5 inhibitors. It also does not have a dangerous interaction with nitrate medications, making it relevant for men who cannot use PDE5 inhibitors for cardiovascular reasons — though all cardiac history should be discussed with your provider before starting.

Cost & Insurance Coverage

Because PT-141 is prescribed off-label and available only as a compounded medication for male use, it is not covered by insurance for this indication.

For context on the full cost and coverage landscape of ED medications — including insurance-eligible options — see our ED & PE Medication Guide.

The Bottom Line

PT-141 is the most evidence-backed of the three novel ED therapies we prescribe at Revive. It has human RCT data, a clear mechanistic rationale, and a meaningful response rate in a population — PDE5 non-responders — who have few other options. It is not a replacement for first-line PDE5 inhibitors, and its 33.5% response rate means it doesn't work for the majority of men who try it. But for the right patient profile, it offers a real pathway where other options have closed.

To understand how PT-141 fits alongside apomorphine and oxytocin as part of a broader off-label ED toolkit, read our hub article: Novel ED Therapies Beyond Viagra.

Frequently Asked Questions